SCHEMBL2303533

SCHEMBL2303533

Cc1csc(-c2nc(N)c3ccsc3n2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.56
ADORA1 P30542 9/20 0.56
CHEK1 O14757 2/20 0.44
AURKA O14965 2/20 0.44
DAPK3 O43293 2/20 0.44
JAK2 O60674 2/20 0.44
ABL1 P00519 2/20 0.44
NTRK1 P04629 2/20 0.44
CSF1R P07333 2/20 0.44
RET P07949 2/20 0.44
IGF1R P08069 2/20 0.44
PDGFRB P09619 2/20 0.44
PIM1 P11309 2/20 0.44
FGFR1 P11362 2/20 0.44
PRKACA P17612 2/20 0.44
KDR P35968 2/20 0.44
MAP2K2 P36507 2/20 0.44
FLT3 P36888 2/20 0.44
MAPK8 P45983 2/20 0.44
CSNK1A1 P48729 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2306306 0.75 ADORA2A (0.60) ADORA2AADORA1NOS1SMN1; SMN2
SCHEMBL27856975 0.73 ADORA2A (0.71) ADORA2AADORA1
SCHEMBL17181116 0.73 ADORA2A (0.55) ADORA2AADORA1CHEK1AURKADAPK3
SCHEMBL14975226 0.73 ADORA2A (0.73) ADORA2AADORA1CHEK1AURKADAPK3
SCHEMBL2301144 0.72 ADORA2A (0.58) ADORA2AADORA1NOS1SMN1; SMN2
SCHEMBL2303619 0.72 ADORA2A (0.60) ADORA2AADORA1
SCHEMBL3299495 0.72 ADORA2A (1.00) ADORA2AADORA1CHEK1AURKADAPK3
SCHEMBL3348239 0.72 ADORA2A (0.70) ADORA2AADORA1NTRK1
SCHEMBL2368763 0.71 ADORA2A (1.00) ADORA2AADORA1CHEK1AURKADAPK3
SCHEMBL3300401 0.71 ADORA2A (1.00) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350092-A1 METHYLENE AMINES OF THIENO Ý2,3-D¨PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2011-08-03 EP disclosed
WO-2010045006-A1 METHYLENE AMINES OF THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-22 WO disclosed
WO-2010045009-A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-22 WO disclosed
WO-2010045009-A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-22 WO disclosed
WO-2010045006-A1 METHYLENE AMINES OF THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-04-22 WO disclosed
US-20100093721-A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093721-A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093702-A1 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093702-A1 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed
US-20100093702-A1 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093721-A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA2B ADORA2A 1/4885ADORA1 4/4885CHEK1 1394/4885
US-20100093702-A1 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA2B ADORA2A 1/4885ADORA1 4/4885CHEK1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.